HAC Pharma is a European specialty pharma company that focuses on delivering high therapeutic value medicines to patients. Founded in 2007, the French company has established itself as an independent pharmaceutical "Exploitant" with a strong track record in the industry. HAC Pharma's unique end-to-end capabilities enable it to effectively market high therapeutic value drugs, particularly in areas with limited alternatives for patients. The company operates with its own sales force in France, targeting specialists in hospital and retail channels within the fields of endocrinology, neurology, gynecology, onco-hematology, and gastroenterology.
HAC Pharma's approach involves distribution, in-licensing, and acquisition deals to bring mature and innovative drugs to the market. It also collaborates with a network of trusted distributors across six European countries, including Spain, Italy, Belgium, Austria, Switzerland, and Portugal. The company positions itself as a partner of choice for integrating products throughout their lifecycle, offering expertise in regulatory and market access strategy, product importation, distribution, as well as marketing and sales strategies.
Given its focus on high therapeutic value medications and its expansion across the European market, HAC Pharma presents an attractive investment opportunity for venture capital firms seeking to support innovative and impactful players in the pharmaceutical and healthcare industries.
There is no investment information
No recent news or press coverage available for HAC Pharma.